[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f-VCfbrG9nYFXQDiadGtxBKiPat5dVKJehRxg-v1Jh9c":8,"$fCYTJA1v3msLVN63FxLnbilByzJ0pEiQZMmLSzUi-KxM":55,"$fQEAqXYXNc6rDAuH2ITixP7ZHncNzXMk1MJrQ1Ew6fOM":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},70330,863254,[],"https://ystcdn.venuertc.com/medical/ystApp/Dlmj9URvs7gXdepZpARivDbqwZwkg06p.png","朱永亮","龙口南山养生谷肿瘤医院","放射科","住院医师",397,0,"靶向和免疫药物在晚期肝癌治疗中的安全用药全指南","","https://ystcdn.venuertc.com/venue/AI/4589078c-20e9-4148-829d-8a08a9f792ec.jpg","\u003Cdiv class=\"material-container\">\n  \u003Ch1 id=\"material_title\" class=\"material-title\">靶向和免疫药物在晚期肝癌治疗中的安全用药全指南\u003C/h1>\n\n  \u003Cdiv class=\"material-intro\">\n    很多人对靶向药物和免疫药物越来越熟悉，它们已成为肝脏肿瘤治疗中的关键一环。靶向药（如仑伐替尼）作用于特定信号通路，免疫检查点抑制剂则可以调动身体自身防御系统。今天，咱们聊这类药物用药中的7个必须注意的细节，帮助你放心用药，规避常见的风险。\n  \u003C/div>\n  \n  \u003C!-- 01 剂型与服用方法 -->\n  \u003Csection class=\"material-section\" style=\"background: linear-gradient(90deg, #f8fafc 0%, #e6f0fa 100%); border-radius:16px; margin-bottom:26px;\">\n    \u003Ch2 class=\"material-section-title\">\u003Cspan class=\"emoji\">💊\u003C/span>01 剂型和服用方法\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      靶向药如仑伐替尼一般为片剂，其它同类药物也多见口服制剂。正确做法：用足量温水整片吞服，避免嚼碎。饭前服用还是饭后服用，具体请看药品说明书，大多数靶向药建议每日固定时间。免疫抑制剂则按说明注射，一般在医院由专业人员操作。\u003Cbr>\n      真实案例：有位患者因将片剂掰碎，导致消化不良，应注意不要自行更改给药方式。\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 02 用药剂量与调整原则 -->\n  \u003Csection class=\"material-section\" style=\"background: linear-gradient(90deg, #f6fafd 30%, #dbeffe 99%); border-radius:16px; margin-bottom:26px;\">\n    \u003Ch2 class=\"material-section-title\">\u003Cspan class=\"emoji\">⏱️\u003C/span>02 用药剂量与调整原则\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      靶向药物和免疫药物剂量设置需个体化。不同体重和肝肾功能的患者，剂量可能不同。正确做法：每次按说明书计量，不能随意增减。医生会根据不良反应（如腹泻、口腔溃疡、骨髓抑制）适当调整，用药过程中如有新不适应及时反馈。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 03 药理作用简明说明 -->\n  \u003Csection class=\"material-section\" style=\"background: linear-gradient(90deg, #fafcfa 30%, #f2f8e6 99%); border-radius:16px; margin-bottom:26px;\">\n    \u003Ch2 class=\"material-section-title\">\u003Cspan class=\"emoji\">🧬\u003C/span>03 药物的作用机制\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      靶向药物（以仑伐替尼为代表）主要通过抑制血管生长因子受体（VEGF Receptor）阻断肿瘤新生血管，从而影响肿瘤的营养供给。免疫检查点抑制剂则解除免疫系统“刹车”，激活T细胞清除异常细胞。两者联用时，各自作用互补，可以提高治疗效果（Finn et al., 2020）。\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 04 用药禁忌和高危人群 -->\n  \u003Csection class=\"material-section\" style=\"background: linear-gradient(90deg, #fdf8fa 30%, #f4e6fc 99%); border-radius:16px; margin-bottom:26px;\">\n    \u003Ch2 class=\"material-section-title\">\u003Cspan class=\"emoji\">🚫\u003C/span>04 用药禁忌与特殊人群注意\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      对仑伐替尼、地舒单抗、免疫抑制剂成分过敏者禁用。孕妇、哺乳期妇女必须暂停或改用安全方案。肾功能不全、肝功能明显异常、心律失常者，需严格在医生指导下监测用药。特别提醒：药物有影响血压、心脏功能的风险，高血压患者和房颤人群不可自行停药或断药。\n      \u003Cbr>\n      \u003Cstrong>正确做法：\u003C/strong>任何身体特殊情况或过敏史必须告知医生，每次药物调整都需医生评估。\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 05 药物相互作用和配伍禁忌 -->\n  \u003Csection class=\"material-section\" style=\"background: linear-gradient(90deg, #f8fcfa 30%, #e6fff0 99%); border-radius:16px; margin-bottom:26px;\">\n    \u003Ch2 class=\"material-section-title\">\u003Cspan class=\"emoji\">⚠️\u003C/span>05 药物相互作用\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      靶向药物（如仑伐替尼）通过肝脏酶（如CYP3A4）代谢，部分药、食物会影响其浓度。酮康唑、利福平、葡萄柚制品等可能增加或减少血药水平。免疫抑制剂与糖皮质激素、大剂量消炎药同用时，可能互相影响免疫活性。\n      \u003Cbr>\n      \u003Cstrong>正确做法：\u003C/strong>用药期间不得自行使用新药或补充剂。所有在用及新加药品、保健品、抗生素、降压药、抗凝药均需告知医生。\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 06 常见不良反应的识别与应对 -->\n  \u003Csection class=\"material-section\" style=\"background: linear-gradient(90deg, #fcfaf8 0%, #ffe8cc 100%); border-radius:16px; margin-bottom:26px;\">\n    \u003Ch2 class=\"material-section-title\">\u003Cspan class=\"emoji\">😷\u003C/span>06 常见不良反应及处理方法\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      靶向药和免疫药物最常见不良反应包括高血压、腹泻、黏膜损伤、皮疹、乏力、骨髓抑制。个别患者会有发热、感染风险。统计显示，仑伐替尼类药物的腹泻发生率可达20%-30%（Kudo et al., 2018），免疫药相关口腔溃疡发病率在10%左右。\n      \u003Cbr>\n      \u003Cstrong>正确做法：\u003C/strong>如出现食欲差、腹泻超3次/天、皮肤破损、明显发热，第一时间联系医生。轻微副作用可适当调整饮食和生活习惯，严重不适及时就诊并调整剂量。\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 07 药品储存和服用遗漏处理 -->\n  \u003Csection class=\"material-section\" style=\"background: linear-gradient(90deg, #f9fcff 30%, #e9f8ff 99%); border-radius:16px; margin-bottom:26px;\">\n    \u003Ch2 class=\"material-section-title\">\u003Cspan class=\"emoji\">📦\u003C/span>07 储存方法和漏服后的补救\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      所有靶向片剂、口服制剂应远离湿热、阳光直射环境，室温（15-30℃）存放，避免受潮。如需分拆使用，优先取密封包装内的药片；开封后需盖紧瓶盖。药品过期或变色变味，禁止继续服用。\n      \u003Cbr>\n      \u003Cstrong>正确做法：\u003C/strong>如忘记服药，想起来后立即补服；已到下次服药时间则跳过，不要一次服两倍剂量。\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 08 使用经验总结与用药安全提醒 -->\n  \u003Csection class=\"material-section\" style=\"background: linear-gradient(90deg, #f6f8fc 15%, #dce4f4 100%); border-radius:16px; margin-bottom:28px;\">\n    \u003Ch2 class=\"material-section-title\">\u003Cspan class=\"emoji\">📝\u003C/span>08 临床用药经验与安全细节\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      \u003Cul style=\"padding-left:22px;\">\n        \u003Cli>临床案例显示，个别老年患者在使用仑伐替尼期间血压升高，经及时调整降压药维持治疗。\u003C/li>\n        \u003Cli>骨转移患者地舒单抗治疗可导致低钙血症，需定期补钙、监测血钙。\u003C/li>\n        \u003Cli>免疫药物联合使用时不良反应风险略高，需动态监测血常规和肝肾功能。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"material-content-highlight\">任何出现异常不适（如严重皮疹、高热、持续腹泻或出血倾向），必须第一时间就医，切勿自行停药。\u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 09 药物优势与安全观总结 -->\n  \u003Csection class=\"material-section\" style=\"background: linear-gradient(90deg, #eaf3e9 15%, #fff 100%); border-radius:16px; margin-bottom:14px;\">\n    \u003Ch2 class=\"material-section-title\">\u003Cspan class=\"emoji\">⭐\u003C/span>09 安全与效果的双重保证\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      靶向药和免疫药物带来的突破已得到确凿数据支持，它们既提高了不少患者的生存期，也对部分患者的生活质量带来帮助（Finn et al., 2020）。不过，疗效的基础必须是科学用药。记住，按医嘱服药，做好自我监测，及时反馈身体异常，才是获得药物最大收益的前提。\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 参考文献 -->\n  \u003Csection class=\"material-section\" style=\"background: linear-gradient(90deg, #fff6e6 10%, #fafcf6 90%); border-radius:16px;\">\n    \u003Ch2 class=\"material-section-title\">📚 参考文献\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      \u003Col style=\"padding-left:30px;\">\n        \u003Cli>Finn, R. S., Ikeda, M., Zhu, A. X., Galle, P. R., Ducreux, M., Kim, T. Y., ... & Cheng, A. L. (2020). Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. \u003Cem>Journal of Clinical Oncology, 38\u003C/em>(26), 2960-2970. https://doi.org/10.1200/JCO.20.01294\u003C/li>\n        \u003Cli>Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., ... & Cheng, A. L. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. \u003Cem>Lancet, 391\u003C/em>(10126), 1163-1173. https://doi.org/10.1016/S0140-6736(18)30207-1\u003C/li>\n        \u003Cli>Rini, B. I., Battle, D., Figlin, R. A. (2019). Immune checkpoint inhibitors in kidney and liver cancer. \u003Cem>Current Opinion in Oncology, 31\u003C/em>(3), 137-142. https://doi.org/10.1097/CCO.0000514\u003C/li>\n      \u003C/ol>\n    \u003C/div>\n  \u003C/section>\n\n\u003C/div>\n\n\u003Cstyle>\n.material-container {\n  max-width: 820px;\n  margin: 36px auto;\n  padding: 30px 34px;\n  font-family: 'Segoe UI', 'Helvetica Neue', Arial, 'PingFang SC', 'Microsoft Yahei', sans-serif;\n  background: #f7fafd;\n  box-shadow: 0 4px 26px rgba(96,122,174,0.09);\n  border-radius: 17px;\n}\n\n.material-title {\n  font-size: 2.35em;\n  color: #234655;\n  font-weight: 700;\n  text-align: center;\n  margin-bottom: 20px;\n  letter-spacing: 1px;\n  padding-top: 10px;\n  padding-bottom: 10px;\n}\n\n.material-intro {\n  font-size: 1.16em;\n  background: linear-gradient(90deg, #edf6fd 70%, #e3fde8 100%);\n  border-radius: 12px;\n  padding: 18px 27px 17px 27px;\n  margin-bottom: 30px;\n  color: #3f595b;\n  box-shadow: 0px 1.5px 8px rgba(255,220,150,0.06);\n}\n\n.material-section {\n  padding: 18px 21px 18px 21px;\n  margin-bottom: 24px;\n  border-radius: 16px;\n}\n\n.material-section-title {\n  font-size: 1.42em;\n  font-weight: 600;\n  color: #24588f;\n  margin-bottom: 12px;\n  display: flex;\n  align-items: center;\n  gap: 11px;\n}\n\n.emoji {\n  font-size: 1.25em;\n}\n\n.material-section-content {\n  font-size: 1.13em;\n  color: #283639;\n  line-height: 2.02;\n  padding-left: 6px;\n}\n\n.material-content-highlight {\n  display: block;\n  background: #e5f7ef;\n  color: #2a7c58;\n  border-left: 4px solid #19a374;\n  padding: 7px 16px;\n  margin-top: 17px;\n  border-radius: 8px;\n  font-weight: 600;\n}\n\n.material-section-content ul {\n  padding-left: 21px;\n  margin-top: 0px;\n  margin-bottom: 10px;\n}\n\n.material-section-content li {\n  margin-bottom: 7px;\n  line-height: 1.7;\n}\n\n@media (max-width: 650px) {\n  .material-container {\n    padding: 15px 4vw;\n  }\n  .material-intro, .material-section {\n    padding-left: 7px;\n    padding-right: 7px;\n  }\n  .material-title {\n    font-size: 1.28em;\n    padding-bottom: 8px;\n  }\n  .material-section-title {\n    font-size: 1.1em;\n  }\n  .material-section-content {\n    font-size: 1em;\n    padding-left: 0px;\n  }\n}\n\u003C/style>","\u003Cdiv class=\"material-container\">\n  \u003Ch1 id=\"material_title\" class=\"material-title\">靶向和免疫药物在晚期肝癌治疗中的安全",516,"2025-11-04 02:04:32","靶向药,免疫药物,晚期肝癌,用药安全,不良反应","本文提供靶向药和免疫药物在晚期肝癌治疗的安全用药指南，涵盖用药禁忌、剂量调整、常见不良反应等要点，帮助患者有效应对肝癌，提高生活质量。","2025-12-07 18:01:48",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]